The Lynx Group

NCCN Conference Highlights

Orlando, FL—Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
Read Article

Orlando, FL—Immunotherapy is now an established option for patients with non–small-cell lung cancer (NSCLC) in the second-line setting and in selected patients in the first-line setting.
Read Article

Orlando, FL—The National Comprehensive Cancer Network (NCCN) has provided guidance for the clinical management of genetic mutation carriers who are identified using multigene panels without endorsing the routine use of these tests outside of research and/or intensive counseling on the risks and benefits of their use.
Read Article

Orlando, FL—Molecular analysis and PD ligand 1 (PD-L1) testing for patients with non–small-cell lung cancer (NSCLC) are critically important. Optimally, multiple biomarker testing should be done at diagnosis, but it also has value before choosing therapy for second-line or later.
Read Article

A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at the 2016 Society of Gynecologic Oncology annual meeting.
Read Article

The evidence blocks were incorporated into the National Comprehensive Cancer Network (NCCN) clinical practice guidelines late last year and act as a visual representation of 5 key measures related to specific recommendations.
Read Article

The updated National Comprehensive Cancer Network (NCCN) guideline (version 2.2016) for the management of advanced melanoma reflects the increasing role of immune checkpoint inhibitors and targeted agents, as more data establish their superior efficacy over traditional chemotherapy.
Read Article

The population of patients with multiple myeloma who are eligible for therapy has been expanded to include asymptomatic patients with certain features, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 3.2016).
Read Article

The chances for further policy changes in healthcare over the next several years are expected to be minimal, said panelists during a roundtable discussion at the 2016 National Comprehensive Cancer Network annual conference.
Read Article

The National Comprehensive Cancer Network (NCCN) has added a new value criterion to its clinical practice guidelines in the form of “Evidence Blocks” for the evaluation of treatment options.
Read Article

Page 1 of 2

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: